TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xspray Pharma AB ( (SE:XSPRAY) ) has shared an update.
Xspray Pharma AB has achieved a significant milestone by completing population pharmacokinetic modeling for its product candidate XS003, demonstrating bioequivalence with the reference drug Tasigna at less than half the dose. This advancement, supported by clinical studies showing improved food interaction and predictable dose response, positions Xspray Pharma to submit a New Drug Application soon, marking a crucial step in expanding its product commercialization strategy.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company focused on developing improved versions of marketed protein kinase inhibitors (PKIs) using its innovative HyNap™ technology. The company aims to lead the market in enhanced PKIs for cancer treatment, with a portfolio that includes candidates like Dasynoc®, XS003-nilotinib, and XS008-axitinib.
Average Trading Volume: 29,830
Current Market Cap: SEK1.77B
For an in-depth examination of XSPRAY stock, go to TipRanks’ Overview page.